Vanguard Capital Management
DYN icon

Vanguard Capital Management’s Dyne Therapeutics DYN Stock Holding History

Vanguard Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140M Sell
6,310,969
-94,100
-1% -$1.75M ﹤0.01% 1359
2026
Q1 		$116M Buy
+6,405,069
New +$110M ﹤0.01% 1389

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management's DYN Position: Q2 2026 in Review

Vanguard Capital Management reduced its Dyne Therapeutics (DYN) stake by 1.5% in Q2 2026, selling an estimated $1.75M and leaving 6,310,969 shares worth $140M. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Vanguard Capital Management first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Vanguard Capital Management held 6,310,969 shares of Dyne Therapeutics worth $140M as of Q2 2026.
  • Vanguard Capital Management sold 94,100 Dyne Therapeutics shares in Q2 2026, an estimated $1.75M.
  • Dyne Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1359 holding.
  • Vanguard Capital Management first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.